Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To compare enalapril (E) and diltiazem (D) efficacy in menopausal women with arterial hypertension (AH) using three methods of blood pressure (BP) measurement.

Material and methods. There was a cross-over randomised study with E and D included 22 menopausal women with AH. E was given at a daily dose of 5-20 mg and D – at a daily dose of 180-360 mg. At baseline and at the end of each treatment period ambulatory blood pressure monitoring (ABPM) was carried out. Self blood pressure measurement (SBPM) was performed during all study period. To assess a steadiness of antihypertensive effect we calculated smoothness index and trough-to-peak ratio based on ABPM data.

Results. Ambulatory 24-h systolic BP and diastolic BP were decreased in the E group (-15.2/-9.6 mm Hg) and in the D group (-10.9/-6.0 mm Hg). E demonstrated a greater antihypertensive effect on SBPM results in the evening. Values of smoothness index on E treatment were slightly higher than on D treatment (0.86±0.15/0.64±0.13 vs 0.67±0.17/0.62±0.15). Trough-to-peak ratio was inconclusive in this study.

Conclusions. Results of the study have shown some advantages of antihypertensive therapy with E compared with these of D in slow release formulation (both drugs at a single daily dose) in menopausal women. A sustained antihypertensive effect without negative influence on circadian BP profile allows to consider E as one of perspective agents for the AH treatment in this type of patients. 

About the Authors

V. M. Gorbunov
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation

A. D. Deev
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation

E. V. Platonova
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation

M. M. Bystrova
State Research center of preventive medicine of Rosmedtechnology, Moscow
Russian Federation


1. Шальнова С.А., Деев А.Д., Вихирева О.В., Оганов Р.Г. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профил заболев и укреп здор 2001;(2):3-7.

2. Matthews K., Meilahn E., Kuller L., et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-6.

3. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998,280(7):605-13.

4. Herrington D.M., Reboussin D.M., Broshihan K.B., et al. Effect of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000,343(8):522-9.

5. Writing group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288(3):321-33.

6. Jochmann N., Stangl K., Garbe E., Baumann G., Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26(16):1585-95.

7. Agabiti-Rosei E., Ambrosioni E., Pirelli A.E. Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension. MADAM study group. Moexipril as Antihypertensive Drug After Menopause. Eur J Clin Pharmacol 1999;55(3):185-9.

8. Massana E., Barbanoj M.J., Moros C., et al. No sex-related pharmacokinetic and pharmacodynamic differences of captopril. Pharmacol Res 1997;36:41-7.

9. Прохорович Е.А., Ткачева О.Н., Адаменко А.Н. Особенности клинического течения и лечения артериальной гипертонии у женщин. Трудный пациент 2006;(8):13-6.

10. Staessen J.A., Byttebier G., Buntinx F., et al. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. JAMA 1997;278(13):1065-72.

11. Asmar R., Zanchetti A. Guidelines for the use of self blood pressure monitoring: a summary report of the first international consensus conference. J Hypertens 2000;18:493- 508.

12. Zuther P., Witte K., Lemmer B. ABPM-FIT and CV-SORT: an easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring. Blood Press Monit 1996;1:347-54.

13. Opie L.H. Angiotensin-Converting Enzyme Inhibitors: the advance continues. New York: Author’s Publishing House, 1999.

14. Shionoiri H., Gotoh E., Miyazaki N., et al. Serum concentration and effects of a single dose of enalapril maleate in patients with essential hypertension. Jpn Circ J 1985;49:46-51.

15. Abrams W.B., Davies R.O., Gomez H.J. Clinical pharmacology of enalapril. J Hypertens 1984; (Suppl 2):31-6.

16. Gavras H., Boillaz J., Waeber B., et al. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet 1981;2:543-7.

17. Bergstrand R., Herlitz H., Johansson S., et al. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol 1985;19:605-11.

18. Salvetti A., Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study. Am J Hypertens 1989;2:352-4.

19. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.

20. Parati G. Blood pressure variability, target organ damage and antihypertensive treatment. J Hypertens 2003;21:1827-30.

21. Rizzoni D., Muiesan M.L., Salvetti M., Castellano M., Bettoni G., Monteduro C., et. al. The smoothness index, but not the trough-to-peak ratio predicts changes in carotid artery wall thickness during antihypertensive treatment. J Hypertens 2001;19:703-11.

22. Mancia G., Parati G. Importance of smooth and sustained blood pressure control in preventing cardiovascular morbidity and mortality. Blood Press Suppl 2001;(3):26-32.

For citation:

Gorbunov V.M., Deev A.D., Platonova E.V., Bystrova M.M. COMPARATIVE EVALUATION OF ENALAPRIL AND DILTIAZEM EFFICACY IN MENOPAUSAL WOMEN WITH ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2007;3(4):15-18. (In Russ.)

Views: 393

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)